BRCA1 and ovarian cancer: However, the success of niraparib in significantly extending the duration of progression-free survival in all platinum-sensitive recurrent ovarian cancer patienrs, (those with and without BRCA1/2 mutations) indicates a great expansion of the population who can benefit from PARP inhibitors.